E-Merge Scientific Information Services’ Post

In a panel discussion with Pharma Focus Europe, Dr. Somesh Sharma, Executive Vice President & Head, Discovery Services, Aragen Life Sciences Ltd., shares his insights on the topic “Innovations in Pharmaceutical R&D: Navigating the Future”. During the discussion, he deep dives into some of the key topics such as adaptive clinical trials on drug design, artificial intelligence for drug repurposing, ethical challenges associated with emerging platforms such as AI, CRISPR for R&D practices and R&D efficiency on the scalability of production processes. Read the full article here - https://lnkd.in/gZmFhzVW     #PharmaFocusEurope #Biopharma #CDMO #Pharmaceuticals #MediaCoverage #PanelDiscussion #researchanddevelopment #ClinicalTrails #AI #CRISPR #Aragen #ArageLifeSciences #AragenInTheMedia

Is AI's role in drug development overhyped or underestimated? 2024 is set to be the year of the AI revolution in pharmaceuticals, but is the impact truly as groundbreaking as it's made out to be? The controversy surrounding AI's role in drug development revolves around the extent of its impact. Some argue that AI's potential is overhyped, leading to inflated expectations, while others believe its true implications are underestimated. This debate raises questions about the actual effectiveness of AI in reshaping the pharmaceutical landscape and its ability to deliver on the promises of efficiency and innovation. As AI continues to gain prominence in healthcare, understanding the real implications of its integration into drug development becomes crucial for shaping the future of the industry. We'd love to hear your thoughts on this debate. #AI #Pharma #artificialintelligence

Discover Pharmaeconomica BV's PREDIT platform, an advanced AI tool revolutionizing drug discovery. PREDIT has identified potent cholinesterase inhibitors and antiviral compounds, accelerating R&D in the pharmaceutical industry. Learn how PREDIT is reducing timelines, enhancing precision, and uncovering new therapeutic opportunities. #DrugDiscovery #AI #Pharmaeconomica #Innovation #R&D

Is AI's role in drug development overhyped or underestimated? 2024 is set to be the year of the AI revolution in pharmaceuticals, but is the impact truly as groundbreaking as it's made out to be? The controversy surrounding AI's role in drug development revolves around the extent of its impact. Some argue that AI's potential is overhyped, leading to inflated expectations, while others believe its true implications are underestimated. This debate raises questions about the actual effectiveness of AI in reshaping the pharmaceutical landscape and its ability to deliver on the promises of efficiency and innovation. As AI continues to gain prominence in healthcare, understanding the real implications of its integration into drug development becomes crucial for shaping the future of the industry. I'd love to hear your thoughts on this debate. #AI #Pharma #artificialintelligence

Our latest article, "PREDIT AI Success Story in Drug Discovery," is now live on ThinkML! In this piece, we delve into the remarkable success of Pharmaeconomica BV's PREDIT platform, an advanced AI tool that is revolutionizing the drug discovery process. PREDIT's innovative approach has led to the identification of potent cholinesterase inhibitors and antiviral compounds, showcasing its potential to accelerate research and development in the pharmaceutical industry. Discover how PREDIT is transforming the landscape of drug discovery by reducing timelines, enhancing precision, and uncovering new therapeutic opportunities. Check it out here: https://lnkd.in/dn-u9xcE #DrugDiscovery #AI #Innovation #Pharmaeconomica #PREDIT #CholinesteraseInhibitors #AntiviralCompounds #HealthcareInnovation #Biotech #Pharmaceuticals

Artificial intelligence (AI) is poised to revolutionize the pharmaceutical industry, according to Inceptive CEO Jakob Uszkoreit. He envisions AI as a game-changer that can streamline drug discovery and development processes, making them more efficient and cost-effective. Uszkoreit asserts that AI has the power to reshape the landscape of pharmaceutical research by expediting every phase of […]

Harnessing AI's power to revolutionize drug development. Capturing the potential of genomics and AI in pharmaceuticals. #GenAIDrugDevelopment #AIinPharma #BiotechInnovation #GenomicsResearch #FutureOfMedicine #Femtosoftitservices https://lnkd.in/dcgVmKpz

‘Novartis CEO explains how AI will impact drug development’ #pharma #pharmaceutical #pharmaceuticals #pharmaceuticalindustry #drugdevelopment #clinicalresearch #clinicaldevelopment #ai #artificialintelligence #ml #machinelearning #stem #scienceandtechnology #technology #generatieveai #biotechnology #biopharmaceutical https://lnkd.in/eMPDcbvZ

post could be: The pharmaceutical industry is embracing generative AI to revolutionize drug discovery, development, and repurposing. With the potential to save time and costs, Gen AI is set to transform the sector. Explore the top use cases and real-life examples in our latest blog. #PharmaInnovation #GenerativeAI #DrugDiscovery #AIinPharma https://lnkd.in/g3AQDRrf

#PharmaIndustry #GenerativeAI The pharmaceutical sector faces challenges in drug discovery and development, with costs reaching $2.3 billion per drug. To tackle this, companies are turning to generative AI for faster drug discovery, clinical trial facilitation, and workflow automation. Learn how Gen AI benefits pharma and its challenges in our latest blog. Explore use cases like drug design, virtual screening, and drug repurposing, with a projected market growth of $1.129 million by 2032. Stay ahead in the pharma industry with generative AI! #AIinPharma #DrugDiscovery https://lnkd.in/g3AQDRrf